INULIN AND SODIUM CHLORIDE
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Inulin is a polysaccharide that is not absorbed from the gastrointestinal tract and is used as a diagnostic agent to measure glomerular filtration rate (GFR) by renal clearance. Sodium chloride provides electrolyte supplementation.
| Metabolism | Inulin is not metabolized; it is excreted unchanged by the kidneys. Sodium chloride is absorbed and distributed; no metabolism. |
| Excretion | Renal: 100% as unchanged drug via glomerular filtration without tubular reabsorption or secretion; biliary/fecal: negligible (<1%) |
| Half-life | Normal renal function: 1.5 hours (range 1–2 h); decreases to 0.5 h with severe renal impairment; used to measure glomerular filtration rate (GFR) |
| Protein binding | Approximately 0% (negligible); does not bind to plasma proteins |
| Volume of Distribution | 0.15–0.25 L/kg (approx. 15–25% of body weight; confined to extracellular fluid); reflects distribution limited to extracellular space |
| Bioavailability | Intravenous: 100%; oral: <1% (not absorbed; used for oral GFR measurement but bioavailability is negligible) |
| Onset of Action | Intravenous: immediate (within minutes) after injection; oral: not applicable (no clinical effect used only as diagnostic agent) |
| Duration of Action | Intravenous: 1–2 hours (clearance from plasma); persists until renal excretion complete; prolonged in renal impairment |
Inulin: 5 g IV bolus followed by continuous infusion at 1.5 mL/min of a 10 g/L solution for GFR measurement. Sodium chloride: 0.9% solution as diluent.
| Dosage form | INJECTABLE |
| Renal impairment | Inulin excretion is renal; no dose adjustment as used for GFR measurement. In renal failure, monitor for hypernatremia from NaCl content. |
| Liver impairment | No specific adjustment required; inulin is not hepatically metabolized. |
| Pediatric use | Inulin: 0.5 mL/kg IV bolus of 10% solution followed by infusion at 0.15 mL/kg/min. Sodium chloride: as per isotonic requirement. |
| Geriatric use | Use standard dosing; consider reduced GFR in elderly; monitor volume and electrolyte status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Inulin is not absorbed systemically; sodium chloride is normal plasma constituent. M/P ratio not applicable. Considered safe during breastfeeding. |
| Teratogenic Risk | Inulin is not absorbed systemically; sodium chloride is physiologic. No known teratogenic risk in any trimester. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | fluid replacement |
| Serious Effects |
Known hypersensitivity to inulin; anuria; severe renal impairment.
| Precautions | Use with caution in patients with known anuria or severe renal impairment due to risk of accumulation. Monitor fluid and electrolyte balance. |
Loading safety data…
| Fetal Monitoring | Monitor fluid balance, electrolytes, renal function during prolonged use; fetal assessment not specifically required. |
| Fertility Effects | No known effects on human fertility. |